Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Mark L. Baum - aVenture Research

Mark L. Baum

AddedMar 31, 2024

UpdatedOct 13, 2026

Mark L. Baum

Mark L. Baum

Founder, Eton Pharmaceuticals

Mark L. Baum's Career

Eton Pharmaceuticals

Public

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

$38.1M

Deer Park, IL, US

Founder

Harrow

Public$283.7MNashville, TN, US

Board Member· Board

Co-Founder

Surface Pharmaceuticals

Series A$46.8MDelaware, US

Founder

Surface Ophthalmics

Series B$40MPleasanton, CA, US

Co-Founder

Melt Pharmaceuticals

Series D$50MBrentwood, TN, US

Board Member· Board

Co-Founder

ImprimisRx

Public$253kCarlsbad, CA, US

Founder

People Similar to Mark L. Baum

Sunil GuptaFounder · Eye-Pharma

Houman HemmatiCo-Founder · Stargazer Pharmaceuticals

Leadership at Eton Pharmaceuticals

Charles CasamentoBoard Member

Sean BrynjelsenCEO

Norbert RiedelBoard Member

Paul MaierBoard Member

Similar to Eton Pharmaceuticals

Eagle PharmaceuticalsWoodcliff Lake, NJ, USInjectables, Pharmaceuticalsest. 2007Eagle PharmaceuticalsWoodcliff Lake, NJ, US · est. 2007

Eagle Pharmaceuticals Inc.: A specialty pharma company, developing and distributing critical care and oncology injectables.

Public · $12.3M134

Leadership at Harrow

Joe TonneCo-Founder

Teresa SparksBoard Member

Similar to Harrow

Eye-PharmaLittle Rock, AR, USDrug Productsest. 2013Eye-PharmaLittle Rock, AR, US · est. 2013

Eye-Pharma, LLC: Innovating affordable ophthalmic drugs through reformulation in Little Rock, AR.

Seed · $145.5k7

MediPrint OphthalmicsSan Diego, CA, USPharmaceuticalsest. 2001MediPrint OphthalmicsSan Diego, CA, US · est. 2001

San Diego-based MediPrint Ophthalmics develops and commercializes proprietary ocular drugs to protect sight.

Series A · $7M7

Alimera SciencesAlpharetta, GA, USPharmaceuticalsest. 2003Alimera SciencesAlpharetta, GA, US · est. 2003

Alimera Sciences Inc.: A biopharmaceutical company specializing in ophthalmic pharmaceuticals.

Public · $304.4M145

EyePointWatertown, MA, USDrug Devicesest. 2008EyePointWatertown, MA, US · est. 2008

EyePoint Pharmaceuticals, a global biopharmaceutical firm, develops drug devices for chronic eye disorders.

Public · $653.8M144

Leadership at Surface Pharmaceuticals

Perry SternbergBoard Member

Dr Adrienne L GravesBoard Member

Similar to Surface Pharmaceuticals

Surface OphthalmicsPleasanton, CA, USEye Drops, Therapeuticsest. 2016Surface OphthalmicsPleasanton, CA, US · est. 2016

Surface Ophthalmics, a biotech firm, innovates ocular disease treatments using patented Klarity delivery.

Series B · $40M5

TearClearCopley, OH, USPharmaceuticalsest. 2015TearClearCopley, OH, US · est. 2015

TearClear: A California-based pharmaceutical firm specializing in ocular surface medication delivery since 2015.

Series B · $52M12

TearSolutionsCharlottesville, VA, USPharmaceuticalsest. 2013TearSolutionsCharlottesville, VA, US · est. 2013

TearSolutions: A pharmaceutical company specializing in dry eye medical solutions.

Series B · $21.1M11

MediPrint OphthalmicsSan Diego, CA, USPharmaceuticalsest. 2001MediPrint OphthalmicsSan Diego, CA, US · est. 2001

San Diego-based MediPrint Ophthalmics develops and commercializes proprietary ocular drugs to protect sight.

Series A · $7M7

Leadership at Surface Ophthalmics

Kamran Hosseini, MD, PhDCo-Founder & CEO

Similar to Surface Ophthalmics

Surface PharmaceuticalsDelaware, USPharmaceuticalsest. 2017Surface PharmaceuticalsDelaware, US · est. 2017

Delaware-based Surface Pharmaceuticals develops biotech solutions for dry eye diseases, serving California.

Series A · $46.8M8

TearClearCopley, OH, USPharmaceuticalsest. 2015TearClearCopley, OH, US · est. 2015

TearClear: A California-based pharmaceutical firm specializing in ocular surface medication delivery since 2015.

Series B · $52M12

Ocular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274

Ocular ScienceManhattan Beach, CA, USEye Care Productsest. 2015Ocular ScienceManhattan Beach, CA, US · est. 2015

Ocular Science®: A leading biotech firm innovating affordable eye care solutions.

Seed · $175.1k46

Leadership at Melt Pharmaceuticals

John BerdahlCo-Founder

Larry DillahaCEO

Similar to Melt Pharmaceuticals

Mirata PharmaceuticalsPlymouth Meeting, PA, USPain Relief, Pharmaceuticalsest. 2017Mirata PharmaceuticalsPlymouth Meeting, PA, US · est. 2017

Mirata Pharmaceuticals: Innovating powerful, opioid-based pain relief solutions for patients and physicians.

Series A · $11M5

Amalgent TherapeuticsChapel Hill, NC, USPain Medicationsest. 2020Amalgent TherapeuticsChapel Hill, NC, US · est. 2020

Amalgent Therapeutics: Innovating safer, effective analgesia alternatives to opioids since 2020.

Quartet MedicineCambridge, MA, USPain Medicationsest. 2013Quartet MedicineCambridge, MA, US · est. 2013

Quartet Medicine: Innovating novel treatments for chronic pain and inflammation.

Series A · $23M7

Tremeau PharmaceuticalsConcord, MA, USPain Therapiesest. 2016Tremeau PharmaceuticalsConcord, MA, US · est. 2016

Massachusetts-based pharmaceutical company specializing in non-opioid pain therapies.

Late Stage Private · $115.2M11

Similar to ImprimisRx

US Specialty FormulationsBethlehem, PA, USPharmaceuticalsest. 2013US Specialty FormulationsBethlehem, PA, US · est. 2013

US Specialty Formulations produces FDA-approved sterile injectable pharmaceuticals for healthcare providers globally.

Angel · $75k14

Amphastar PharmaceuticalsRancho Cucamonga, CA, USBiologics, Pharmaceuticalsest. 1996Amphastar PharmaceuticalsRancho Cucamonga, CA, US · est. 1996

Amphastar Pharmaceuticals: A leading US-based specialty pharma company, expert in developing injectable and inhalation products.

Public · $300M1.6k

Auxilius PharmaHudson, MA, USPharmaceuticalsest. 2018Auxilius PharmaHudson, MA, US · est. 2018

Auxilius Pharma: Innovating cost-effective solutions to meet unmet healthcare needs.

MediPrint OphthalmicsSan Diego, CA, USPharmaceuticalsest. 2001MediPrint OphthalmicsSan Diego, CA, US · est. 2001

San Diego-based MediPrint Ophthalmics develops and commercializes proprietary ocular drugs to protect sight.

Series A · $7M7

Amphastar PharmaceuticalsRancho Cucamonga, CA, USBiologics, Pharmaceuticalsest. 1996

Amphastar PharmaceuticalsRancho Cucamonga, CA, US · est. 1996

Amphastar Pharmaceuticals: A leading US-based specialty pharma company, expert in developing injectable and inhalation products.

Public · $300M1.6k

Assertio HoldingsNewark, CA, USPharmaceuticalsest. 2020Assertio HoldingsNewark, CA, US · est. 2020

Innovative Newark-based pharmaceutical company developing orphan drugs and therapeutic solutions for US patients.

Public · $1B42

US Specialty FormulationsBethlehem, PA, USPharmaceuticalsest. 2013US Specialty FormulationsBethlehem, PA, US · est. 2013

US Specialty Formulations produces FDA-approved sterile injectable pharmaceuticals for healthcare providers globally.

Angel · $75k14